Inside Lemnisca’s Big Leap For Digital Twins To Make Biotech More Scalable

Why It Matters

Digital twins can dramatically reduce bioprocess development time and cost, accelerating commercialization in a rapidly expanding biotech sector.

Key Takeaways

• Digital twins simulate fermentation at industrial scale
• Hybrid model merges cell behavior and process physics
• In‑house wet lab creates feedback loop for model refinement
• Reduces experiments from hundreds to virtual thousands
• Aims to serve diverse molecules across multiple industries

Pulse Analysis

The global bioprocessing market is projected to grow 11.4% annually, reaching $228 billion by 2033, while India’s bio‑economy has expanded sixteen‑fold to $165.7 billion. Yet moving a fermentation from a 1‑litre bench‑top to a 100,000‑litre fermenter remains fraught with uncertainty because temperature, oxygen and mixing behave differently at scale. Traditional scale‑up relies on costly trial‑and‑error, limiting speed and inflating capital expenditure. Digital‑twin technology, which creates a virtual replica of the biological and physical environment, promises to bridge this gap.

Lemnisca’s platform couples a hybrid model—combining mechanistic cell‑growth equations with CFD‑style process simulations—with an on‑site wet lab that continuously feeds real‑world data back into the twin. This closed‑loop approach lets engineers run thousands of virtual experiments in the time it takes to conduct a single lab run, dramatically cutting development cycles and material waste. While firms such as Differential Bio and Invert Bio offer similar services abroad, Lemnisca is the first Indian player to integrate both software and laboratory infrastructure, giving it a unique value proposition for domestic and export customers.

If Lemnisca can demonstrate reliable scale‑up for a pilot molecule in 2025, it could unlock rapid, cost‑effective production of high‑value bioproducts—from nutraceutical omega‑3s to cosmetic squalene—across multiple sectors. The ability to de‑risk fermentation projects aligns with the Indian government’s ₹10,000 cr Biopharma Shakti scheme and the broader $300 billion biotech opportunity projected for 2030. However, juggling two complex endeavors—software development and wet‑lab operations—means execution risk remains high, and success will hinge on data quality, model fidelity, and adoption by large‑scale manufacturers.